Assessment of Haemostasis in patients undergoing emergent neurosurgery by rotational Elastometry and standard coagulation tests: a prospective observational study

Christoph Ellenberger 1, Najia Garofano 1, Gleicy Barcelos 1, John Diaper 1, Gordana Pavlovic 1 and Marc Licker 1,2*

Abstract

Background: Rotational elastometry (ROTEM) has been shown useful to monitor coagulation in trauma patients and in major elective surgery. In this study, we aimed to evaluate the utility of ROTEM to identify hemostatic disturbances and to predict the need for transfusion, compared with standard coagulation tests (SCTs) in patients undergoing emergent neurosurgery.

Methods: Over a four-year period, adult patients who met criteria for emergent neurosurgery lasting more than 90 min were included in the study. Blood was collected preoperatively and analyzed with SCTs (international normalized ratio [INR], fibrinogen concentration, prothrombin time [PT or Quick], partial thromboplastine time [PTT], fibrinogen concentration and platelet count), and ROTEM assays. Correlations between SCTs and ROTEM parameters as well as receiver operating characteristic curves were performed to detect a coagulopathic pattern based on standard criteria and the need for transfusing at least 3 units of packed red blood cells (PRBCs).

Results: In a cohort of 92 patients, 39 (42%) required ≥3 PRBCs and a coagulopathic pattern was identified in 32 patients based on SCTs and in 19 based on ROTEM. There was a strong correlation between PTT and INTEM coagulation time ($R = 0.76$) as well as between fibrinogen concentrations and FIBTEM maximal clot firmess ($R = 0.70$). The need for transfusion (≥3 PRBCs) was best predicted by the maximal clot firmess of EXTEM and FIBTEM (AUC of 0.72 and 0.71, respectively) and by fibrinogen concentration (AUC of 0.70).

Conclusions: In patients undergoing emergent neurosurgery, ROTEM analysis provides valid markers of early coagulopathy and predictors of blood transfusion requirements.

Keywords: Brain injury, Trauma, Transfusion, Anesthesia, Bleeding

Background

Surgical complications increase the cost of health care worldwide and directly contribute to patient morbidity and mortality [1]. After cranial or spinal interventions, the most frequent postoperative complication is bleeding requiring blood transfusion, followed by re-intervention and failure to wean from the ventilator [2]. In the particular settings of brain injury following trauma or neurosurgical procedures, abnormal patterns of coagulation may develop. Depending on different diagnostic criteria, the incidence of acute traumatic coagulopathy varies between 7% and 86% after isolated traumatic brain injury [3] and it is associated with single-and multiple organ dysfunction, greater transfusion requirements, higher mortality and, prolonged stay in the intensive care unit (ICU) [4].

According to the current hypothesis, trauma brain injuries are associated with a combination of hyper- and
hypocoagulable states. The initial brain damage triggers the release of tissue factor and initiate the coagulation process which is further amplified and sustained by secondary brain ischemic and hemorrhagic injuries [5]. Concomitantly, hypoperfusion and endothelium damage result in thrombomodulin release with stimulation of protein C pathway leading to the inhibition of activated co-factors V and VIII and decreased thrombin generation leading to a decrease in fibrin formation [6]. Likewise, intracranial hypertension and brain ischemia in the context of brain hematoma/tumor, have also been shown to initiate the coagulation cascade in non-trauma patients [6, 7]. Variable tissue release of thrombin and plasminogen activator, along with activation of the protein C pathway and platelet dysfunction may all concur to these acute hemostatic disorders. Moreover, the efficacy of antifibrinolytic agents in reducing blood losses in patients with brain trauma, subarachnoid hemorrhage or intracranial tumor emphasizes the importance of hyperfibrinolysis in patients undergoing major neurosurgery [8–10].

Standard coagulation tests (SCTs) including the platelet count, plasma fibrinogen levels, the international normalized ratio (INR), partial thromboplastin time (PTT) and prothrombin time (PT or Quick test) are the mainstay in the anesthesiologist’s armoury to assess preoperatively hemostatic disturbances and to predict the need transfusion [11]. More recently, viscoelastic hemostatic assays (VHA) such as thromboelastography (TEG) and rotational elastometry (ROTEM) have emerged as suitable monitors of the coagulation process during the perioperative period [12, 13]. These VHA Point-Of-Care (POC) devices both measure and display the viscoelastic properties in whole blood samples from the initial phase of fibrin formation to clot retraction and fibrinolysis. In contrast with SCTs performed in plasma samples and in remote laboratory settings, these POC-VHA deliver bedside information on the dynamic interactions between plasmatic factors and circulating blood cells. In cardiac surgery, the implementation of POC-VHA has been associated with a reduction in blood transfusion requirements [14]. So far, no study has been conducted on the utility of POC-VHA in patients undergoing emergent neurosurgery [15].

The purpose of this observational study was to compare preoperative SCTs to ROTEM-derived parameters in patients scheduled for emergent neurosurgical interventions. We hypothesized that the use of ROTEM may identify specific coagulation abnormalities and could be considered as a suitable alternative for SCTs.

**Methods**

**Patient population**

From January 2011 to December 2014, adult patients (>18 years) undergoing emergent neurosurgical procedures at the University Hospital of Geneva were included in this prospective trial if they fulfilled the following criteria: 1) intracranial intervention, 2) necessity to proceed to surgery within 6–8 h after diagnostic work up, 3) surgery lasting at least 90 min. The exclusion criteria were a life expectancy <24 h and/or any associated pathology requiring a combined surgical procedure (e.g., multiple trauma). The indications for surgical operations were: severe traumatic brain injury, space-occupying intracerebral hematoma or expanding/ruptured aneurysm, tumoral process associated with raising intracranial pressure or neurological deficit. A severe isolated traumatic brain injury was defined by an Abbreviated Injury Scale for head (AIShead) > 3, with an AIS for extracranial injuries (AISextracranial) < 3, where 3 is rated as “serious” [16].

The study was approved by the local institutional research ethics board (CCER N°10–128) and informed consent was waived given the emergency context and the fact that ROTEM testing was routinely performed in all surgical patients at high risk of bleeding.

**Study design**

This study was performed as a prospective unblinded observational investigation. Intraoperatively, the hemostatic therapy (fresh frozen plasma [FFP], prothrombin complex concentrate [PCC], platelet concentrates, activated factor VII) was guided by the results ROTEM testing as well as by clinical judgement (Fig. 1). This algorithm had been implemented 2 years before the start of the study in our department, for all types of major surgery [17].

**Patient management**

Anesthesia was induced and maintained intravenously with propofol, sufentanil and rocuronium or atracurium. After tracheal intubation, mechanical ventilation was delivered with a low tidal volume (6–8 ml/kg of ideal body weight) and a low positive end-expiratory pressure (4–8 cmH2O) while the respiratory frequency was adjusted to maintain normocapnia (end-expiratory carbon dioxide pressure between 38 and 42 mmHg). All patients were equipped with two peripheral venous catheters, an invasive radial arterial line, a nasopharyngeal temperature probe and a bladder catheter. Intraoperatively, body temperature was maintained by forced-air warming (Bair Hugger™ 3 M, St. Paul, USA) and by warming intravenous fluids. Pneumatic compression boots were placed after anesthesia induction to prevent deep vein thrombosis.

A standardized fluid management approach guided by invasive hemodynamic parameters was aimed to maintain euvolemia with the infusion of isotonic fluids administration (2–3 ml/kg during anesthesia induction followed by a continuous rate of 1.5–2.5 ml/kg/h and additional fluid volume if necessary). Blood losses were substituted in a 2:1 ratio with a balanced crystalloid...
solution (Ringer-acetate; B. Braun, AB). One or two units of PRBC were administered if the hemoglobin concentration decreased below 90 g/L.

### Coagulation testing

Venous blood samples for SCTs were collected preoperatively in 5 mL citrated tubes in the emergency department. The SCTs were performed in the settings of the Central Laboratory and included the followings: PTT, PT (Quick), INR, and plasma fibrinogen concentration (Clauss method; Siemens-Dade Behring Healthcare Diagnostics, Marburg, Germany). Platelet count, hemoglobin concentration and hematocrit were measured in EDTA blood samples with a Coulter Counter (Beckman Coulter Diagnostics, Brea, CA, USA).

For ROTEM analysis, blood was sampled in the operating theater on citrated tubes from the radial arterial catheter with a continuous heparin-free sodium chloride flushing system. ROTEM analyses were performed within minutes of blood sampling by anesthesia nurses or physicians trained to perform the ROTEM tests according to the manufacturer’s instructions (ROTEM®; TEM Innovations GmbH, Germany) [18]. Four ROTEM analyses were performed in parallel: an extrinsically activated assay with recombinant tissue factor (EXTEM), an intrinsically activated test using phospholipid–ellagic acid (INTEM), a platelet inhibition test using Cytocholasin D (FIBTEM) and an aprotinin-based test to detect ongoing hyperfibrinolysis (APTEM). The following ROTEM variables were measured: clotting time (CT [sec], the time from start of measurement until formation of a clot with an amplitude of 2 mm); clot formation time (CFT [sec], time from the end of CT [amplitude of 2 mm] until a clot firmness of 20 mm is achieved); alpha angle, angle between the centre line and a tangent to the curve through the 2 mm amplitude point; maximum clot firmness (MCF [mm]), the final strength of the clot, resulting from the interaction of fibrin, activated platelets and factor XIII and, clot amplitude after 15 min (CA15 [mm], amplitude of clot firmness after 15 min).

### Measurements and study endpoints

Using SCTs, coagulopathy was defined as one or more of the following results: Quick (PT) < 70%, INR > 1.3, aPTT >35 s, fibrinogen <1.5 g/L, and platelet count <100,000 /mcL [18]. Using ROTEM parameters, coagulopathy was defined with two or more of the following results: EXTEM CT > 80 s, EXTEM CFT > 159 s, EXTEM MCF < 50 mm, INTEM CT > 240 s, INTEM CFT > 110 s, INTEM MCF < 50 mm, and FIBTEM MCF < 9 mm [18–21].

Demographic, clinical and surgical data, Glasgow Coma Scale (GCS) score upon hospital admission, administration of fluids, blood transfusion products (FFPs, PCC, thrombo-pheresis) and other hemostatic agents (recombinant factor VII [rFVII], tranexamic acid [TA]) were all recorded from the anesthesia, surgical and emergency charts. On the morning of the first day following surgery, venous blood
was collected to perform SCTs and ROTEM analysis. In addition, the electronic medical files were examined to report hospital and ICU length of stay as well as major postoperative complications (in-hospital mortality, acute respiratory failure, infections, renal failure, thromboembolic events, myocardial infarct, and heart failure).

**Statistical analysis**
In our institutional database, we found that 85% of patients undergoing emergent neurosurgical procedures were transfused, the median PRBC transfusion was 2 units and 42% of patients received at least 3 RBCs. Hence, the cohort of patients was divided into two groups, high bleeders (HB) receiving at least 3 PRBCs or requiring re-operation for hematoma drainage and, low bleeders (LB) receiving less than 3 PRBCs and not requiring re-operation for hemostasis. Summary descriptive statistics are expressed as frequencies (and percentages, %), medians (and interquartile range, IQ25–75%), or means (and standard deviations, SD). Clinical data and coagulation parameters as well as postoperative outcome were compared between the two groups (HB and LB) with the chi-squared test for categorical variables and with the two-sided unpaired Student t test (normal distribution) or Wilcoxon rank test (non-normal distribution) for continuous variables.

The Pearson product-moment correlation coefficient was used to assess the agreement between SCTs and ROTEM parameters that mostly follow a normal distribution and measure similar aspects of the coagulation cascade (i.e. PT, aPTT and INR with CT; fibrinogen and platelet with alpha angle and MCF).

The area under the curve (AUC) of the receiver operating characteristic (ROC) curves was determined for variables that were significantly related with PRBC transfusion. The ROC analysis evaluates diagnostic/predictive accuracy by changing the laboratory cut-off point throughout the potential range of the test under study to examine the specificity and sensitivity of the tests [22]. All analyses were performed using STATA 14 software (Stata Corp, College Station, TX, USA) and statistical significance was specified as a two-tailed type I error (P value) set below the 0.05 level.

**Results**
During a 3-year period, 112 patients undergoing emergent neurosurgery were consecutively enrolled in this prospective study. Twenty patients were excluded due to minor or short lasting interventions (minor procedures, N = 5; surgery lasting less than 90 min, N = 15). In total, data from 92 patients were analyzed, their mean age was 52 years (SD 17.7 yrs), 49 (53%) patients were male and 29 (32%) were admitted to the hospital with severe trauma brain injury. The median duration of the neurosurgical procedures was 180 min (IQ25–75, 113–249 min) and in-hospital mortality was 27.1%.

No patient required re-operation for hematoma drainage and 39 (42%) required three or more PRBCs (HB group). As shown in Table 1, the HB group (N = 39) was characterized by a higher proportion of trauma patients, lower Glasgow Coma Score, higher heart rate and lower hemoglobin level, compared with the LB group (N = 53).

Before surgery, a coagulopathic pattern was identified in 32 patients (34.8%) based on SCTs, 19 (48.7%) in the HB group and 13 (24.5%) in the LB group. Based on ROTEM analysis a coagulopathic pattern was identified in 19 patients (20.6%), 15 (38.5%) in the HB group and 4

| Table 1 Demographic and clinical characteristics of patients undergoing emergency neurosurgery |
|-----------------------------------------------|
| Characteristics | High Bleeders (N = 39) | Low Bleeders (N = 53) | P-value |
|-----------------|------------------------|----------------------|--------|
| Demographic data |                        |                      |        |
| Age, years | 51.3 (18.5) | 52.5 (17.3) | 0.746c |
| Weight, kg | 71.4 (13.9) | 75.4 (15.2) | 0.204c |
| Height, cm | 170.7 (9.5) | 170.5 (9.9) | 0.925c |
| Body Mass index, kg/(m²) | 24.4 (3.0) | 25.7 (4.3) | 0.146c |
| Sex, male | 22 (56.4) | 27 (50.9) | 0.604 |
| Admission for Trauma | 19 (48.7) | 10 (18.9) | 0.005 |
| ASA 3 & 4 | 33 (84.6) | 38 (71.7) | 0.145 |
| Comorbidities |                        |                      |        |
| Arterial hypertension | 9 (23.1) | 16 (30.2) | 0.449 |
| Chronic kidney disease | 1 (2.6) | 1 (1.9) | 1.000a |
| Diabetes mellitus | 2 (5.1) | 9 (17.0) | 0.110a |
| Cardiac arrhythmia | 1 (2.6) | 5 (9.4) | 0.237a |
| Preoperative medications |                  |                      |        |
| Antiplatelet | 8 (20.5) | 10 (18.9) | 0.844 |
| Anti-vitamine K | 3 (7.7) | 2 (3.8) | 0.647a |
| Thrombine-inhibitor | 5 (12.8) | 7 (13.2) | 0.957 |
| Hemodynamics upon arrival in the operating theater |                  |                      |        |
| Systolic arterial pressure, mmHg | 132 (34.0) | 140 (29.4) | 0.231c |
| Heart rate, beat/min | 89 (22) | 80 (19) | 0.026c |
| Laboratory tests |                        |                      |        |
| Hemoglobin, g/dL | 10.7 (2.1) | 11.6 (2.1) | 0.047c |
| Lactate, mm/L | 1.4 (0.8–2.2) | 1.0 (0.8–1.7) | 0.115d |

ASA American Society Association physical status classification, TRISS Trauma and Injury Severity Score
Data given as number (percentage) unless otherwise indicated:
[a]data given as mean (standard deviation)
[b]data given as median (range)
[c]Chi-squared tests were used for statistical tests unless otherwise indicated;
[d]student t test
[e]Wilcoxon rank-sum test
[f]Fisher exact test
(7.6%) in the LB group. Agreement between SCTs and ROTEM analysis in detecting (or not) a coagulopathic pattern was achieved in 61 patients (66.3%).

Preoperatively, there was a strong correlation between PTT and both CT and alpha angle of INTEM ($R = 0.76$ and 0.73, respectively) and between fibrinogen plasma concentrations and the MCF of FIBTEM ($R = 0.70$). There was a moderate correlation between preoperative platelet count and the MCF of EXTEM ($R = 0.61$). The correlation between preoperative PT/INR and the CT and alpha angle of EXTEM was weak ($< 0.60$).

Regarding preoperative coagulation testing (Table 2), patients in the HB group presented significantly lower plasma fibrinogen concentrations, lower Quick values and higher INR whereas ROTEM analysis demonstrated significantly prolonged CT and CFT at the EXTEM assay as well as lower MCF and CA15 at the EXTEM, INTEM, FIBTEM and ATEM assays, compared with the LB group. As shown in Table 3, surgical indications were similar in the two groups. In the HB group surgical time was longer and patients were more likely to be treated with FFPs, fibrinogen, TA and PCC than the LBs.

Transfusion with at least 3 PRBCs was best predicted by the Glasgow Coma Score (AUC of 0.74, and 95%CI between 0.58–0.89). As shown in figs. 2 and 3, the AUC of the ROC analysis for identifying patients receiving at least 3 PRBCs was 0.72 for MCF-EXTEM (95%CI 0.61–0.83), 0.71 for MCF-FIBTEM (95%CI 0.60–0.82), 0.70 for INTEM-MCF (95%CI 0.59–0.81) and, 0.70 for fibrinogen levels (95%CI 0.58–0.82). Removing patients treated with anticoagulant and/or antiplatelet drug did not

### Table 2 Preoperative coagulation parameters of patients undergoing emergent neurosurgery

|                         | High Bleeders (N = 39) | Low Bleeders (N = 53) | P-value |
|-------------------------|------------------------|-----------------------|---------|
| **Standard coagulation tests** |                        |                       |         |
| Platelets, $10^3$/mL$^a$ | 178 (87)               | 194 (86)              | 0.403$^c$ |
| Quick, %                | 82 (62–94)             | 94 (79–100)           | 0.018   |
| INR, a.u.$^a$           | 1.22 (0.30)            | 1.07 (0.08)           | 0.005$^c$ |
| Partial Thromboelastogram, sec | 34 (27–38)       | 30 (26–32)            | 0.383   |
| Fibrinogen, g/L$^a$     | 2.5 (1.2)              | 3.1 (0.9)             | 0.006$^c$ |
| Coagulopathy, (%)$^b$   | 19 (61.3)              | 13 (33.3)             | 0.032$^d$ |
| **Thromboelastometry**  |                        |                       |         |
| EXTEM                   |                        |                       |         |
| CT (s)                  | 65 (50–88)             | 52 (47–62)            | 0.002   |
| CFT (s)                 | 136 (91–217)           | 104 (74–129)          | 0.001   |
| alpha Angle             | 70 (60–78)             | 73.5 (69.5–78)        | 0.129   |
| MCF (mm)                | 54.5 (45–63)           | 64 (57–69)            | <0.001  |
| INTEM                   |                        |                       |         |
| CT (s)                  | 157 (133–180)          | 154 (141–167)         | 0.681   |
| CFT (s)                 | 88 (68–134)            | 69 (57–97)            | 0.005   |
| alpha Angle             | 73 (64–79)             | 77 (74–79)            | 0.037   |
| MCF (mm)                | 57 (50–63)             | 65 (57–70)            | 0.001   |
| FIBTEM                  |                        |                       |         |
| MCF (mm)                | 12 (7–16)              | 16 (14–22)            | <0.001  |
| Coagulopathy, (%)$^b$   | 15 (45.6)              | 4 (9.3)               | <0.001$^d$ |

$^a$arbitrary unit, CT coagulation time, CFT clot formation time, INR international normalized ratio, MCF maximal clot firmness

Data given as median (range) unless otherwise indicated;

$^b$data given as mean (standard deviation)

$^c$data given as number (percentage)

Wilcoxon rank-sum test was used for statistical tests unless otherwise indicated;

$^d$data given as number (percentage)

Student $t$ test was used for statistical tests unless otherwise indicated;

$^e$Chi-squared tests

| Surgical features                        | High Bleeders (N = 39) | Low Bleeders (N = 53) | P-value |
|------------------------------------------|------------------------|-----------------------|---------|
| Decompressive craniectomy                | 10 (25.6)              | 14 (26.4)             | 0.933   |
| Subdural hematoma                        | 11 (28.2)              | 14 (26.4)             | 0.849   |
| Subarachnoid haemorrhage                 | 12 (30.8)              | 13 (24.5)             | 0.469   |
| Subdural hematoma & subarachnoid haemorrhage | 6 (15.4)            | 7 (13.2)              | 0.767   |
| Surgery time, (min)$^c$                  | 190 (159–280)          | 156 (90–230)          | 0.012$^d$ |

| Intraoperative Fluids                   | High Bleeders (N = 39) | Low Bleeders (N = 53) | P-value |
|------------------------------------------|------------------------|-----------------------|---------|
| Crystalloids, ml/min$^a$                 | 21.8 (10.4)            | 18.5 (16.4)           | 0.272$^p$ |
| Colloids, ml/min$^c$                     | 0 (0–28)               | 0 (0–8)               | 0.312$^p$ |

| Blood products & haemostatic therapy    |                        |                       |         |
|------------------------------------------|                        |                       |         |
| Blood transfusion                        | 39 (100)               | 28 (52.8)             | <0.001  |
| Units/patient transfused$^d$             | 5 (3–7)                | 1 (1–2)               | <0.001$^d$ |
| Fresh frozen plasma                      | 27 (69.2)              | 12 (22.6)             | <0.001  |
| Units/patient transfused$^d$             | 3 (2–7)                | 2 (1–25)              | 0.002$^d$ |
| Platelets                                | 11 (28.2)              | 9 (17.0)              | 0.197   |
| Units/patient transfused$^d$             | 2 (1–3)                | 2 (1–3)               | 0.812$^d$ |
| Prothrombin Complex Concentrate          | 7 (18.0)               | 2 (3.8)               | 0.033$^p$ |
| 10$^7$ units/patient treated$^d$         | 1.8 (1.2–2.4)          | 3 (2.4–3.6)           | 0.133$^p$ |
| Fibrinogen                               | 20 (74.4)              | 11 (20.8)             | <0.001  |
| g/patient treated$^d$                    | 4 (2–6)                | 4 (2–4)               | 0.205$^d$ |
| Recombinant Factor VII                   | 3 (7.7)                | 0 (0)                 | 0.073$^p$ |
| mg/patient treated$^d$                   | 7 (5–9)                | 0 (0–0)               | NA      |
| Tranexamic acid                          | 7 (18.0)               | 1 (1.9)               | 0.009$^p$ |
| g/patient treated$^d$                    | 1.5 (1.0–2.0)          | 1.0 (1.0–1.0)         | 0.368$^d$ |

Data given as number (percentage) unless otherwise indicated. Chi-squared tests were used for statistical tests unless otherwise indicated;

$^a$data given as mean (standard deviation)

$^b$data given as median (range)

$^c$Wilcoxon rank-sum test

$^d$Fisher exact test
significantly alter the main ROC results, the largest AUC were still achieved for fibrinogen measurements (0.71, 95%CI 0.57–0.86), INTEM-MCF (0.74, 95%CI 0.61–0.86) and MCF-FIBTEM (0.75, 95%CI 0.62–0.87). The accuracy in predicting transfusion ≥3 PRBCs, was equal or superior with ROTEM-derived parameters compared with SCTs (Table 4). Indeed, 64.1% patients were correctly classified as HB (or LB) based on SCTs, whereas the accuracy for correct classification was 69.6% when using ROTEM based parameters. To predict the need for transfusion (≥3 PRBCs), ROTEM analysis was more sensitive than SCTs (78.9% versus 59.4), whereas specificities were similar (67.1% and 66.7% respectively). The best thresholds to discriminate patients requiring transfusion (≥3 PRBCs vs < 3 PRBCs) were: fibrinogen blood concentration < 1.5 g/L, EXTEM CFT > 159 s, INTEM CFT > 110 s and FIBTEM MCF < 9 mm.

Coagulation parameters of SCTs and ROTEM analysis all normalized 18–24 h after surgery (Table 5), except the platelet count that remained decreased by 28% (IQ25–75, 12–41%) compared with preoperative values and, it was lower in the HB than in the LB group. Postoperative clinical outcome did not differ significantly between the two groups, pneumonia (24%) and bleeding (10%) being the most frequent complications.
Discussion

This cohort study provides for the first time some insight into the coagulation pattern of patients undergoing emergent neurosurgical interventions. Our data showed that: (i) a coagulopathic pattern was detected preoperatively in 35% patients based on SCTs and in 21% based on ROTEM analysis; (ii) the results obtained with ROTEM fairly correlated with SCTs; (iii) ROTEM analysis had a higher sensitivity to predict the need for transfusion of at least 3 PRBC than SCTs; (iv) abnormalities in ROTEM parameters were useful to guide the correction of hemostatic abnormalities.

In elective neurosurgery, preexisting coagulation disorders are rarely diagnosed (less than 3%) and the sensitivity of any SCTs in predicting clinical outcome, particularly the need for homologous transfusion, is less than 10% [23, 24]. Before emergent neurosurgical interventions, these SCTs are time consuming and their diagnostic utility is limited to the initial formation of fibrin strands [11]. In contrast, POC-VHAs such as ROTEM provide...
on-line information from the initiation to full development of blood clot including subsequent fibrinolysis and this emerging testing modality have proven its superiority in managing acutely bleeding patients compared with SCTs [25]. As expected, we found a good correlation between PTT and intrinsically activated ROTEM tests (INTEM CT and alpha angle) at the early stage of coagulation whereas plasma fibrinogen levels correlated fairly well with the clot amplitude of the FIBTEM test (MCF and CA15). In elective surgical pediatric cases, Haas et al. reported a strong correlation between fibrinogen plasma levels and FIBTEM CA ($R = 0.88$) and between PT and INTEM CT [26]. Likewise, in ninety patients admitted with variable degree of trauma, Rugeri et al. also observed a good correlation between SCTs and ROTEM parameters, namely between PT and EXTEM CA as well as between fibrinogen levels and FIBTEM CA [27].

In the present study, 32 out of 92 patients presented prolonged PT/PTT, low levels of fibrinogen and/or low
platelet counts that have been used as criteria to define an acute coagulopathy. With the POC-VHA, abnormalities in coagulation profile were reported in 19 patients based on ROTEM parameters using validated cut-off values recommended by the manufacturer [18] and, agreement between SCTs and ROTEM was achieved in 66.3% for the diagnosis of trauma-induced coagulopathy. In a recent multicenter trial including trauma patients, Hagemo et al. confirmed that clot amplitude with ROTEM analysis was a valid marker of an ongoing coagulopathy, with optimal thresholds of FIBTEM CA < 9 mm and EXTEM CA5 < 37 mm [28].

Since small intracranial hematomas or ongoing bleeding may have devastating effects, transfusion of at least 3 PRBCs was used as a surrogate to define major bleeding among our neurosurgical patients [29–31]. This contrasts with cardiac surgery, liver transplantation and multiple trauma where cut-off values for major bleeding are ranging from 4 to 10 PRBCs and are associated with a high burden of morbidity and mortality [32, 33]. Not surprisingly, the largest AUC (0.74) were obtained in patients with the lowest Glasgow Coma Score that reflected the severity of the initial brain injuries and the consequent trauma-induced coagulopathy with alteration in POC-VHA and SCTs. Our data demonstrated that the amplitude of clot formation at the FIBTEM and EXTEM assays were the most accurate ROTEM-derived parameters in predicting transfusion requirement and were at least equivalent to the results obtained with SCTs using well-established thresholds. Interestingly, preoperative treatment with anticoagulants and antiplatelets did not alter the predictive value of ROTEM-derived parameters for transfusion requirement. This could be explained by the fact that, clinicians, being aware of these drug-induced hemostatic effects, administered FFP and/or thrombopheresis to minimize intraoperative bleeding.

These findings are consistent with studies involving patients with multiple trauma, although different thresholds of clot amplitude have been identified with platelet-inhibited and tissue factor-activated assays (FIBTEM and EXTEM). Davenport reported that, EXTEM CA5 ≤ 37 mm and FIBTEM ≤ 35 mm was a better predictor of massive transfusion (≥ 10 PRBCs) than INR > 1.2 (71% vs 43%) [19]. In other cohort studies, a satisfactory detection rate for massive transfusion was reported using thresholds of fibrinogen ≤ 1.9 g/L, FIBTEM CA5 < 9 mm and FIBTEM MCF < 7 mm [28, 34].

Besides early identification of coagulation deficits, there is now growing evidence that POC-VHA coupled with determination of blood hemoglobin concentration facilitates goal-directed blood management and hemostatic therapy, particularly in cardiac surgery and in massive trauma [35, 36]. In a randomized controlled trial including 100 high-risk cardiac surgical patients, Weber et al. demonstrated that hemostatic therapy based on viscoelastic and aggregometric testing was associated with reduced exposure to allogenic blood products, faster weaning from the ventilator and earlier discharge from the ICU, compared with empiric hemostatic therapy based on SCTs and clinical judgement [37]. In the present study, we

| Table 5 Postoperative coagulation data and clinical outcome in patients undergoing emergent neurosurgery | High Bleeders (N = 39) | Low Bleeders (N = 53) | P-value |
|---|---|---|---|
| Coagulation testing one day after surgery | | | |
| Platelets, 10^3/ml* | 109 (38) | 159 (65) | 0.002† |
| Quick, % * | 90 (72–99) | 92 (75–100) | 0.611a |
| INR, a.u* | 1.11 (0.13) | 1.12 (0.12) | 0.578† |
| Fibrinogen, g/L* | 4.0 (1.2) | 3.9 (1.2) | 0.326f |
| EXTEM CT | 57 (42–72) | 55 (40–70) | 0.641 |
| EXTEM MCF | 62 (50–74) | 59 (48–71) | 0.284 |
| INTEM MCF | 66 (59–75) | 62 (56–71) | 0.248 |
| FIBTEM MCF | 58 (51–65) | 57 (50–64) | 0.968 |
| Clinical Outcome (in-hospital) | | | |
| Composite Mortality - Morbidity | 47 (88.7) | 15 (38.5) | 0.001 |
| Mortality | 14 (35.9) | 11 (20.8) | 0.107 |
| Cardiovascular outcomes | | | |
| Myocardial infarction/ischemia | 1 (2.6) | 0 (0.0) | 0.424a |
| Cardiac arrhythmia | 3 (7.7) | 5 (9.4) | 1.000a |
| Thromboembolic complication | 1 (2.6) | 2 (3.8) | 1.000a |
| Acute heart failure | 1 (2.6) | 2 (3.8) | 1.000a |
| Respiratory complications | | | |
| Pneumonia | 8 (20.5) | 14 (26.4) | 0.424 |
| Acute Respiratory Distress Syndrome | 0 (0.0) | 1 (1.9) | 1.000a |
| Mechanical ventilation, days* | 3 (1–11) | 3 (1–13) | 0.673b |
| Renal dysfunction | | | |
| Reduction in GFR > 25% | 6 (15.4) | 3 (5.7) | 0.161c |
| Other complications | | | |
| Infection | 3 (7.7) | 5 (9.4) | 1.000a |
| Postoperative bleeding | 6 (15.4) | 7 (13.2) | 0.767 |
| Length of stay | | | |
| ICU, days* | 10 (3–19) | 5.5 (3–16) | 0.391b |
| Hospital, days* | 31 (18–37) | 23.5 (15–32) | 0.173b |

Data given as number (percentage) unless otherwise indicated. GFR glomerular filtration rate, ICU intensive care unit
Chi-squared tests were used for statistical tests unless otherwise indicated;
*Data given as median (range)
†Wilcoxon rank sum test
Fisher exact test
*mean (standard deviation)
Survivors only
+unpaired Student t test
implemented a simple algorithm based on perioperative ROTEM analysis to correct the early coagulation disorders. Accordingly, the administration of platelet concentrates, PCC, FFP, fibrinogen and tranexamic acid was guided using specific thresholds that have been previously reported [23, 27–29]. This individualized goal-directed hemostatic approach resulted in normalizing both ROTEM-derived parameters and SCTs on the first day after surgery, except for the platelet count. Considering the multifactorial pathophysiology of perioperative hemorrhage during neurosurgery, SCTs are of limited diagnostic value and have a long turnaround time exceeding 60 min [38]. In contrast, POC-VHA results are rapidly available and, by analyzing the interactions between plasma coagulation factors and circulating blood cells, they provide valuable information regarding the causes of perioperative hemorrhage [39].

This prospective study has several limitations. First, this was a single center study with a relatively small and heterogenous sample of patients with different acute brain disorders, comorbidities and treatments. Second, the different timings of blood sampling for coagulation testing could likely influence the results but reflected the practical aspects of managing these critically-ill surgical patients. Indeed, blood for ROTEM analysis was collected later than for SCTs, after the initiation of resuscitative/stabilization interventions and closer to the start of surgery, therefore ROTEM parameters might better characterize the ongoing coagulation abnormalities. Third, a quarter of patients were on preoperative antiplatelet or anticoagulant therapy and, ROTEM analysis was poorly suited to detect any impairment in platelet adhesion/aggregation and in vitamin K-dependent coagulation factor formation that could explain the observed poor correlation between INR/Quick and EXTEM CT. Finally, hyperfibrinolysis could not be detected in this cohort since tranexamic acid was administered prophylactically in 18% of HB patients, namely those with severe brain trauma.

Conclusions

Implementation of POC-VHAs provided useful indicators for detecting and correcting hemostatic abnormalities in patients undergoing emergent neurosurgery. ROTEM assays were equal or superior to SCTs in identifying patients with acute coagulopathy and in predicting intraoperative blood transfusion requirement. Future studies should be directed to evaluate the clinical impact of repeated POC-VHA measurements in guiding haemostatic treatment in emergent neurosurgery.

Abbreviations

AIS: Abbreviated Injury Scale; AUC: area under the curve; CA15: clot amplitude after 15 min; CFT: clot firmness time; CT: coagulation time; FFP: fresh frozen plasma; HB: high bleeder; ICU: intensive care unit; INR: international normalized ratio; LB: low bleeder; MCF: maximum clot firmness; POC: Point-Of-Care; PPC: prothrombin complex concentrate; PRBC: packed red blood cell; PT: prothrombin time; PTT: partial thromboplastine time; rFVII: recombinant factor; ROTEM: Rotational elastometry; SCT: standard coagulation test; TA: tranexamic acid; TEG: thromboelastograph; VHA: viscoelastic hemostatic assay

Acknowledgements

Authors would like to thank all the anesthesia nursing team for their continuous and valuable contribution in performing the ROTEM tests and providing dedicated care to patients in the operating rooms.

Funding

This study was supported by the Research Fund of the department of Anesthesiology, Pharmacology & Intensive Care of the University Hospital of Geneva.

Availability of data and materials

The raw data of the current study are available from the corresponding author on request.

Authors’ contributions

CE and NG equally contributed to this work and are considered as co-first author; CE and NG designed the study and drafted the manuscript; CE performed statistical analysis. BG, JD and GP discussed the design of the study, participated to data collection and corrected the initial version of the manuscript. ML designed the study protocol, supervised data collection, drafted the initial and the final versions of the manuscript. All authors read and approved the final version.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the University Hospital of Geneva (Registration N° CER 10–128), with a waiver for informed consent given the emergency context and the fact that ROTEM testing was routinely performed in all surgical patients at high risk of bleeding.

Consent for publication

Not applicable. No individual patient data are reported.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 6 July 2017 Accepted: 19 October 2017 Published online: 24 October 2017

References

1. Eappen S, Lane BH, Rosenberg B, Lipstz SA, Sadoff D, Matheson D, Berry WR, Lestar M, Gawande AA. Relationship between occurrence of surgical complications and hospital finances. JAMA. 2013;309(15):1599–606.
2. Rolston JD, Han SJ, Lau CY, Berger MS, Parsa AT. Frequency and predictors of complications in neurological surgery: national trends from 2006 to 2011. J Neurosurg. 2014;120(3):736–45.
3. Epstein DS, Mitra B, Cameron PA, Fitzgerald M, Rosenfeld JV. Acute traumatic coagulopathy in the setting of isolated traumatic brain injury: definition, incidence and outcomes. Br J Neurosurg. 2014;1–5.
4. Chhabra G, Sharma S, Subramanian A, Agrawal D, Sinha S, Mukhopadhyay AK. Coagulopathy as prognostic marker in acute traumatic brain injury. J Emerg Trauma Shock. 2013;6(3):180–5.
5. Simmons JW, Powell MF. Acute traumatic coagulopathy: pathophysiology and resuscitation. Br J Anaesth. 2016;117(suppl 3):iii31–43.
6. Gerlach R, Krause M, Seifert V, Goerlinger K. Hematicotic and hemorrhagic problems in neurosurgical patients. Acta Neurochir 2009, 151(8):873–900.
7. Noss K, Poon WS, Chan DT, Ip CP. Tissue plasminogen activator expression in meningiomas and glioblastomas. Clin Neurol Neurosurg. 2005;107(4):206–300.
8. Gabor T, Magheru C, Emery E, Delrin JM. Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis. Acta Neurochir (Wien) 2012, 154(1):1–9; discussion 9.
9. Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015;10(5):CD004896.

10. Hoooda B, Chouhan RS, Rath GP, Bithal PK, Suri A, Lamsal R. Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma. J Clin Neurosci. 2017;41:132–8.

11. Fowler A, Perry DJ. Laboratory monitoring of haemostasis. Anaesthesia. 2015;70 Suppl 1:68-72, e24.

12. Raman VV, Kasivisvanathan R, Madhivathanan PR. A clinician’s guide to point-of-care coagulation testing in perioperative period. Br J Hosp Med (Lond). 2015;76(12):690–5.

13. Abrahams JM, Torchia MB, McGarvey M, Putt M, Baranov D, Sinson GP. Perioperative assessment of coagulability in neurosurgical patients using thromboelastography. Surg Neurol 2002, 58(1):5–11; discussion 11-12.

14. Webster CF, Zacharowski K, Meybohm P, Adam EH, Hofer S, Brun K, Volk T, Kreuer S. Hemotherapy algorithms for coagulopathic cardiac surgery patients. Clin Lab. 2014;60(6):1059–63.

15. Beynon C, Unterberg AW, Sakowitz OW. Point of care coagulation testing in neurosurgery. J Clin Neurosci. 2015;22(2):252–7.

16. Palmer CS, Gabbie BJ, Cameron PA. Defining major trauma using the 2008 abbreviated injury scale. Injury. 2016;47(1):109–15.

17. Sartorius D, Waeber JL, Pavlovic G, Frei A, Diaper J, Myers P, Cassina T, Licker M. Thromboelastometry (ROTEM(R)) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. Crit Care. 2014;18(5):S18.

18. Rahe-Meyer N, Solomon C, Vorweg M, Becker S, Stenger K, Winterhalter M, Davenport R, Manson J, De’Ath H, Platton S, Coates A, Allard S, Hart D, Creagh E, Lang T. Multicentric comparison of single portion reagents and liquid reagents for thromboelastometry. Br J Anaeth. 2014;112;10:308–15.

19. Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde HJ, Lakner M. Multi-centre evaluation of various thromboelastometry (ROTEM(R)) systems and HELMIA hemostatic screening in adults undergoing elective, non-cardiac surgery. PLoS One. 2015;10(12):e0139139.

20. Davenport R, Manson J, De’Ath H, Platton A, Allard S, Hart D, Pearse R, Pasie KL, MacCallum P, et al. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med. 2013;41(12):2562–6.

21. Schoch H, Solomon C, Traintinger S, Nienaber U, Becker S, Lammers J, Winterhalter M, Davenport R, Manson J, De’Ath H, Platton S, Coates A, Allard S, Hart D, Creagh E, Lang T. Multicentric comparison of single portion reagents and liquid reagents for thromboelastometry. Blood Coagul Fibrol. 2014;25(3):218–22.

22. Haastrup SE, Spielmann N, Mauch J, Madjdpour C, Spielmann N, Mauch J, Madjdpour C, Speer O, Schmugge M, Weiss M. The place of viscoelastic testing in clinical practice. Br J Hosp Med (Lond). 2015, 76 Suppl 1:68-72, e24.

23. Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Anaesth. 2016;116(3):339–42.

24. Haas T, Spielmann N, Mauch J, Mauch J, Madjdpour C, Speer O, Schmugge M, Weiss M. The place of viscoelastic testing in clinical practice. Br J Anaesth. 2016;116(3):339–42.

25. Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Anaesth. 2016;117(3):483–92.

26. Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Anaesth. 2016;116(3):339–42.

27. Hans GA, Besser MW. The place of viscoelastic testing in clinical practice. Br J Anaesth. 2016;117(3):483–92.

28. Kozek-Langenecker S, Solomon C. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM(R))-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14(2):R55.

29. Deppe AC, Weber C, Zimmermann J, Kuhn BW, Slottosch I, Liakopoulos OJ, Choi YH, Wahlers T, Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res. 2016;203(2):424–33.

30. Da Luz LT, Nascimento B, Shankarakutty AK, Rizoli S, Adhikari NK. Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. Crit Care. 2014;18(5):S18.

31. Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde HJ, Lakner M. Multi-centre evaluation of various thromboelastometry (ROTEM(R)) systems and HELMIA hemostatic screening in adults undergoing elective, non-cardiac surgery. PLoS One. 2015;10(12):e0139139.

32. Weil IA, Seicean S, Neuhauser D, Schiltz NK, Seicean A. Use and utility of preoperative hemostatic screening and patient history in adult series. 1988;24(4857 Jun. 3):1285–91.

33. Cywinski J, Alster JM, Miller C, Vogt DP, Parker BW. Prediction of intraoperative transfusion requirements during orthotopic liver transplantation and the influence on postoperative patient survival. Anesth Analg. 2014;118(2):428–37.

34. Schoch H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM(R))-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14(2):R55.

35. Deppe AC, Weber C, Zimmermann J, Kuhn BW, Slottosch I, Liakopoulos OJ, Choi YH, Wahlers T, Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res. 2016;203(2):424–33.

36. Da Luz LT, Nascimento B, Shankarakutty AK, Rizoli S, Adhikari NK. Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review. Crit Care. 2014;18(5):S18.

37. Weber CF, Gotlinger K, Meininger D, Hermann E, Bingold T, Montz A, Cohn LH, Zacharowski K. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117(3):331–47.

38. Toulon P, Ozier Y, Ankri A, Feron MH, Leroux G, Samama CM. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost. 2009;101(2):394–401.

39. Chandler WL. Emergency assessment of hemostasis in the bleeding patient. Int J Lab Hematol. 2013;35(3):339–43.